Results 61 to 70 of about 66,456,090 (253)

Organ-specific accumulation and toxicity analysis of orally administered polyethylene terephthalate microplastics

open access: yesScientific Reports
Microplastics (MPs), plastic particles with a diameter of 
Dongseon Kim   +10 more
doaj   +1 more source

A low-cost, open-source device to evaluate limb stiffness in a rabbit model of cerebral palsy

open access: yesFrontiers in Bioengineering and Biotechnology
BackgroundMovement disorders such as cerebral palsy (CP) are frequently associated with joint and muscle stiffness, often evaluated using subjective clinical methods like the Modified Ashworth Scale or Tardieu Scale.
Preston R. Steele   +7 more
doaj   +1 more source

Preclinical neuroimaging: an overview

open access: yes, 2005
Preclinical applications in neuroradiology are rapidly growing. This work briefly reviews the aims, methods and research fields in which preclinical neuroradiology units are involved. Specifically we will describe applications in pharmacological research,
MARZOLA, Pasquina   +3 more
core   +1 more source

Future directions in preclinical and translational cancer neuroscience research

open access: yes, 2020
Recent advances in cancer neuroscience necessitate the systematic analysis of neural influences in cancer as potential therapeutic targets in oncology.
Gil, Ziv   +26 more
core   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

open access: yesFEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés   +2 more
wiley   +1 more source

TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations

open access: yesCommunications Medicine
Background Activating mutations in the epidermal growth factor receptor (EGFR), particularly exon 19 deletions and L858R mutation, are frequently observed in non-small cell lung cancer (NSCLC) and confer sensitivity to EGFR-tyrosine kinase inhibitors ...
Hidefumi Kasuga   +6 more
doaj   +1 more source

Methodological Rigour in Preclinical Research: Implications for its Scientific Validity and Biomedical Progress

open access: yes, 2019
Preclinical research using animals often precedes and informs clinical trials; however, most attempts to translate findings from “bench-to-bedside” fail.
Ramirez, Francisco Daniel
core   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Remodeling of Intrahepatic Ducts in a Model of Caroli Syndrome: Is Scar Carcinoma a Consequence of Laplace’s Law?

open access: yesMedical Sciences, 2019
Caroli syndrome, characterized by saccular dilatation of intrahepatic ducts and congenital hepatic fibrosis, is without therapy in part due to its ultra-rare prevalence and the apparent lack of availability of a suitable experimental model. While the PCK
Bharvi M. Chavre   +8 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy